Insider Transactions in Q3 2021 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 27
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,112
-5.37%
|
$333,696
$33.1 P/Share
|
|
Sep 26
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,541
-1.22%
|
$149,853
$33.31 P/Share
|
|
Sep 26
2021
|
Jayne B. Hart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,216
-1.97%
|
$73,128
$33.31 P/Share
|
|
Sep 26
2021
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
865
-1.55%
|
$28,545
$33.31 P/Share
|
|
Sep 26
2021
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,514
-1.71%
|
$115,962
$33.31 P/Share
|
|
Sep 26
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,426
-1.79%
|
$113,058
$33.31 P/Share
|
|
Sep 26
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,633
-1.3%
|
$119,889
$33.31 P/Share
|
|
Sep 25
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,907
-3.09%
|
$392,931
$33.31 P/Share
|
|
Sep 25
2021
|
Jayne B. Hart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,878
-3.34%
|
$127,974
$33.31 P/Share
|
|
Sep 25
2021
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
346
-0.62%
|
$11,418
$33.31 P/Share
|
|
Sep 25
2021
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,746
-3.17%
|
$222,618
$33.31 P/Share
|
|
Sep 25
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,311
-0.68%
|
$43,263
$33.31 P/Share
|
|
Sep 25
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,747
-3.38%
|
$321,651
$33.31 P/Share
|
|
Sep 23
2021
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
49,390
-5.84%
|
$1,679,260
$34.76 P/Share
|
|
Sep 23
2021
|
Paul J Diaz President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
445,439
+34.51%
|
-
|
|
Sep 23
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
200
-0.07%
|
$7,000
$35.06 P/Share
|
|
Sep 21
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,977
+14.8%
|
-
|
|
Sep 21
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,398
+16.82%
|
-
|
|
Sep 21
2021
|
Mark Verratti Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,571
+11.82%
|
-
|
|
Sep 21
2021
|
Nicole Lambert Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,870
+25.45%
|
-
|
|
Sep 21
2021
|
Jayne B. Hart Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,598
+18.62%
|
-
|
|
Sep 17
2021
|
Jayne B. Hart Officer |
SELL
Open market or private sale
|
Direct |
67,446
-22.63%
|
$2,225,718
$33.72 P/Share
|
|
Sep 17
2021
|
Jayne B. Hart Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
77,000
+18.12%
|
$2,002,000
$26.49 P/Share
|
|
Aug 27
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
945
-0.74%
|
$32,130
$34.5 P/Share
|
|
Aug 25
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,058
-0.95%
|
$103,972
$34.81 P/Share
|
|
Aug 25
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,233
-0.96%
|
$75,922
$34.81 P/Share
|
|
Aug 25
2021
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,082
-0.69%
|
$36,788
$34.81 P/Share
|
|
Aug 25
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,123
-0.87%
|
$38,182
$34.81 P/Share
|
|
Aug 25
2021
|
Jayne B. Hart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,148
-1.41%
|
$39,032
$34.81 P/Share
|
|
Aug 24
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
30,000
-11.43%
|
$1,050,000
$35.57 P/Share
|
|
Aug 24
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+10.25%
|
$810,000
$27.07 P/Share
|
|
Aug 23
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-9.4%
|
$1,750,000
$35.32 P/Share
|
|
Aug 23
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.38%
|
$1,350,000
$27.07 P/Share
|
|
Aug 13
2021
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
58,820
-12.82%
|
$1,882,240
$32.79 P/Share
|
|
Aug 10
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
3,250
-1.0%
|
-
|
|
Aug 05
2021
|
S. Louise Phanstiel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+23.08%
|
$1,380,000
$23.34 P/Share
|
|
Aug 05
2021
|
S. Louise Phanstiel Director |
SELL
Open market or private sale
|
Direct |
47,881
-43.72%
|
$1,675,835
$35.04 P/Share
|
|
Aug 05
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
28,225
-10.82%
|
$987,875
$35.57 P/Share
|
|
Aug 05
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,225
+9.77%
|
$762,075
$27.07 P/Share
|
|
Aug 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-9.47%
|
$1,750,000
$35.41 P/Share
|
|
Aug 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.48%
|
$1,350,000
$27.07 P/Share
|
|
Aug 03
2021
|
Dennis Langer Director |
SELL
Open market or private sale
|
Direct |
30,000
-25.1%
|
$1,020,000
$34.75 P/Share
|
|
Aug 03
2021
|
Dennis Langer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+20.06%
|
$750,000
$25.39 P/Share
|
|
Aug 03
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-4.93%
|
$1,700,000
$34.27 P/Share
|
|
Aug 03
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+4.57%
|
$1,250,000
$25.38 P/Share
|
|
Aug 03
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,983
-4.41%
|
$524,405
$35.14 P/Share
|
|
Jul 13
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
43,295
-8.04%
|
$1,428,735
$33.72 P/Share
|
|
Jul 13
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,295
+7.09%
|
$1,125,670
$26.49 P/Share
|
|
Jul 12
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-9.52%
|
$1,650,000
$33.55 P/Share
|
|
Jul 12
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.56%
|
$1,300,000
$26.49 P/Share
|